Clinical Trial Programme
We are currently investigating the safety and efficacy of arimoclomol in Niemann-Pick type C (NPC). NPC is a rare, lysosomal storage disorder which affects around 1 in 120,000 newborns.
Are you a patient, caregiver or healthcare professional? Do you need more information about our approach? We want to hear from you! Click here to contact us.